0 XP   0   0   0

Duopharma Biotech Bhd
Buy or Sell?

Welcome Invester! I guess you are interested in Duopharma Biotech Bhd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's start. I'm going to help you getting a better view of Duopharma Biotech Bhd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Duopharma Biotech Bhd even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Duopharma Biotech Bhd is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Duopharma Biotech Bhd. The closing price on 2022-09-28 was RM1.28 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Duopharma Biotech Bhd Daily Candlestick Chart


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Duopharma Biotech Bhd.

1.1. Profitability

An important factor of a company's health is the profitability.

1.1.1. Net Profit Margin

Measures how much net profit Duopharma Biotech Bhd generates for each RM1 of revenue.

  • Above 10% is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Net Profit Margin of 10.1% means that RM0.10 for each RM1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Duopharma Biotech Bhd:

  • The MRQ is 9.0%. The company is making a profit. +1
  • The TTM is 10.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ9.0%TTM10.1%-1.2%
TTM10.1%YOY10.8%-0.6%
TTM10.1%5Y10.0%+0.2%
5Y10.0%10Y12.6%-2.6%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ9.0%4.6%+4.4%
TTM10.1%7.8%+2.3%
YOY10.8%11.6%-0.8%
5Y10.0%7.7%+2.3%
10Y12.6%7.7%+4.9%
1.1.2. Return on Assets

Shows how efficient Duopharma Biotech Bhd is using its assets to generate profit.

  • Above 5% is considered healthy (always compare to Pharmaceuticals industry mean).
  • 1.5% Return on Assets means that Duopharma Biotech Bhd generated RM0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Duopharma Biotech Bhd:

  • The MRQ is 1.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.4%TTM1.5%-0.1%
TTM1.5%YOY1.5%0.0%
TTM1.5%5Y1.5%0.0%
5Y1.5%10Y2.1%-0.6%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4%0.8%+0.6%
TTM1.5%1.4%+0.1%
YOY1.5%1.7%-0.2%
5Y1.5%1.5%0.0%
10Y2.1%1.5%+0.6%
1.1.3. Return on Equity

Shows how efficient Duopharma Biotech Bhd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy (always compare to Pharmaceuticals industry mean).
  • 2.6% Return on Equity means the company generated RM0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Duopharma Biotech Bhd:

  • The MRQ is 2.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.6%TTM2.8%-0.2%
TTM2.8%YOY2.5%+0.2%
TTM2.8%5Y2.6%+0.2%
5Y2.6%10Y2.9%-0.4%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6%1.7%+0.9%
TTM2.8%2.3%+0.5%
YOY2.5%3.1%-0.6%
5Y2.6%2.6%0.0%
10Y2.9%2.2%+0.7%

1.2. Operating Efficiency of Duopharma Biotech Bhd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Duopharma Biotech Bhd is operating (creating products, providing services etc).

  • Measures how much profit Duopharma Biotech Bhd makes for each RM1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operating Margin of 13.2% means the company generated RM0.13  for each RM1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Duopharma Biotech Bhd:

  • The MRQ is 13.2%. The company is operating less efficient.
  • The TTM is 13.6%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ13.2%TTM13.6%-0.4%
TTM13.6%YOY15.1%-1.5%
TTM13.6%5Y13.9%-0.2%
5Y13.9%10Y17.1%-3.3%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ13.2%-5.6%+18.8%
TTM13.6%1.8%+11.8%
YOY15.1%7.9%+7.2%
5Y13.9%7.2%+6.7%
10Y17.1%8.0%+9.1%
1.2.2. Operating Ratio

Measures how efficient Duopharma Biotech Bhd is keeping operating costs (creating products, providing services etc) low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 87.0% means that the operating costs are RM0.87for each RM1 in net sales.

Let's take a look of the Operating Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 0.870. The company is less efficient in keeping operating costs low.
  • The TTM is 0.864. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.870TTM0.864+0.005
TTM0.864YOY0.850+0.014
TTM0.8645Y0.865-0.001
5Y0.86510Y0.832+0.033
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8701.304-0.434
TTM0.8641.276-0.412
YOY0.8501.182-0.332
5Y0.8651.202-0.337
10Y0.8321.237-0.405

1.3. Liquidity of Duopharma Biotech Bhd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Duopharma Biotech Bhd is able to pay off short-term debts (debts due within 1 year) when selling its assets.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 220.5% means the company has RM2.20 in assets for each RM1 in short-term debts.

Let's take a look of the Current Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 2.205. The company is able to pay all its short-term debts. +1
  • The TTM is 2.163. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.205TTM2.163+0.042
TTM2.163YOY2.597-0.434
TTM2.1635Y2.168-0.005
5Y2.16810Y3.045-0.877
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2052.183+0.022
TTM2.1631.827+0.336
YOY2.5971.921+0.676
5Y2.1681.787+0.381
10Y3.0451.696+1.349
1.3.2. Quick Ratio

Measures if Duopharma Biotech Bhd is able to pay off short-term debts (debts due within 1 year). But only using the most liquid assets (assets that can be quickly converted to cash).

  • Above 1 is considered healthy (always compare to Pharmaceuticals industry mean)
  • A Quick Ratio of 133.5% means the company can pay off RM1.34 for each RM1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 1.335. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.248. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.335TTM1.248+0.087
TTM1.248YOY1.644-0.396
TTM1.2485Y1.007+0.242
5Y1.00710Y1.084-0.078
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3350.819+0.516
TTM1.2481.090+0.158
YOY1.6441.148+0.496
5Y1.0071.004+0.003
10Y1.0840.963+0.121

1.4. Solvency of Duopharma Biotech Bhd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Duopharma Biotech Bhd assets are financed with debt

  • Below 1 (100%) is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Debt to Asset Ratio of 0.47 means that Duopharma Biotech Bhd assets are financed with 47.0% credit (debt) and the remaining percentage (100% - 47.0%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 0.470. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.472. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.470TTM0.472-0.002
TTM0.472YOY0.415+0.057
TTM0.4725Y0.418+0.054
5Y0.41810Y0.326+0.092
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4700.371+0.099
TTM0.4720.357+0.115
YOY0.4150.4150.000
5Y0.4180.408+0.010
10Y0.3260.382-0.056
1.4.2. Debt to Equity Ratio

Measures if Duopharma Biotech Bhd is able to pay off its debts by using shareholders equity (total assets - total liabilities).

  • Below 2 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Debt to Equity ratio of 88.7% means that company has RM0.89 debt for each RM1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 0.887. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.893. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.887TTM0.893-0.006
TTM0.893YOY0.710+0.183
TTM0.8935Y0.727+0.166
5Y0.72710Y0.545+0.182
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8870.586+0.301
TTM0.8930.542+0.351
YOY0.7100.528+0.182
5Y0.7270.655+0.072
10Y0.5450.630-0.085

2. Market Valuation of Duopharma Biotech Bhd

2. Earnings
2.1. Price to Earnings Ratio
  • Compares the company's stock price to its earnings.
  • Above 15 is considered overpriced but is hard to determine (always use industry average).
  • A PE ratio of 15 means the investor is paying $15 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Duopharma Biotech Bhd:

  • The EOD is 17.354. Neutral. Compare to industry.
  • The MRQ is 16.270. Neutral. Compare to industry.
  • The TTM is 21.615. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD17.354MRQ16.270+1.085
MRQ16.270TTM21.615-5.345
TTM21.615YOY47.888-26.273
TTM21.6155Y31.947-10.333
5Y31.94710Y39.348-7.401
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD17.35415.429+1.925
MRQ16.27016.819-0.549
TTM21.61515.298+6.317
YOY47.88818.156+29.732
5Y31.94712.625+19.322
10Y39.34811.597+27.751
2.2. Price Earnings to Growth Ratio
  • Measures how expensive or cheap the stock is compared to its predicted growth
  • Lower is better
  • A PEG ratio of 1 means the investor is paying a fair price for the stock

Let's take a look of the Price Earnings to Growth Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 1.829. Seems overpriced? -1
  • The TTM is 2.081. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ1.829TTM2.081-0.251
TTM2.081YOY5.426-3.345
TTM2.0815Y1.615+0.466
5Y1.61510Y3.902-2.287
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8290.097+1.732
TTM2.0810.072+2.009
YOY5.4260.002+5.424
5Y1.6150.011+1.604
10Y3.9020.011+3.891

2. Books
2.3. Price to Book Ratio
  • Shows if the stock is under or overvalued compared to it's book value (total assets - total liabilities).
  • At or below 1 is considered healthy
  • A PB ratio of 3 means the investor is paying $3 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Duopharma Biotech Bhd:

  • The EOD is 1.899. Good. +1
  • The MRQ is 1.781. Good. +1
  • The TTM is 2.319. Good. +1
Trends
Current periodCompared to+/- 
EOD1.899MRQ1.781+0.119
MRQ1.781TTM2.319-0.539
TTM2.319YOY4.626-2.307
TTM2.3195Y3.100-0.781
5Y3.10010Y4.828-1.729
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD1.8992.556-0.657
MRQ1.7812.803-1.022
TTM2.3192.817-0.498
YOY4.6263.826+0.800
5Y3.1002.908+0.192
10Y4.8282.964+1.864

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Duopharma Biotech Bhd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Per Share--0.6740.668+1%0.666+1%0.610+11%0.525+28%
Current Ratio--2.2052.163+2%2.597-15%2.168+2%3.045-28%
Debt To Asset Ratio--0.4700.4720%0.415+13%0.418+12%0.326+44%
Debt To Equity Ratio--0.8870.893-1%0.710+25%0.727+22%0.545+63%
Eps--0.0170.018-7%0.017+2%0.016+9%0.014+19%
Gross Profit Margin---0.469-0.454-3%-0.325-31%-0.514+9%-0.373-21%
Net Profit Margin--0.0900.101-12%0.108-17%0.100-10%0.126-29%
Operating Margin--0.1320.136-3%0.151-13%0.139-5%0.171-23%
Operating Ratio--0.8700.864+1%0.850+2%0.865+1%0.832+4%
Pb Ratio1.899+6%1.7812.319-23%4.626-62%3.100-43%4.828-63%
Pe Ratio17.354+6%16.27021.615-25%47.888-66%31.947-49%39.348-59%
Peg Ratio--1.8292.081-12%5.426-66%1.615+13%3.902-53%
Price Per Share1.280+6%1.2001.545-22%3.080-61%1.900-37%2.224-46%
Quick Ratio--1.3351.248+7%1.644-19%1.007+33%1.084+23%
Return On Assets--0.0140.015-7%0.015-9%0.015-10%0.021-34%
Return On Equity--0.0260.028-7%0.025+1%0.026-1%0.029-13%
 EOD+0 -3MRQTTM+9 -7YOY+7 -95Y+8 -810Y+7 -9

3.2. Fundamental Score

Let's check the fundamental score of Duopharma Biotech Bhd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1517.354
Price to Book Ratio (EOD)Between0-11.899
Net Profit Margin (MRQ)Greater than00.090
Operating Margin (MRQ)Greater than00.132
Quick Ratio (MRQ)Greater than11.335
Current Ratio (MRQ)Greater than12.205
Debt to Asset Ratio (MRQ)Less than10.470
Debt to Equity Ratio (MRQ)Less than10.887
Return on Equity (MRQ)Greater than0.150.026
Return on Assets (MRQ)Greater than0.050.014
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Duopharma Biotech Bhd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.362
Ma 20Greater thanMa 501.300
Ma 50Greater thanMa 1001.350
Ma 100Greater thanMa 2001.336
OpenGreater thanClose1.260
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in MYR. All numbers in thousands.

Summary
Total Assets1,204,377
Total Liabilities566,271
Total Stockholder Equity638,106
 As reported
Total Liabilities 566,271
Total Stockholder Equity+ 638,106
Total Assets = 1,204,377

Assets

Total Assets1,204,377
Total Current Assets529,583
Long-term Assets529,583
Total Current Assets
Cash And Cash Equivalents 143,600
Net Receivables 177,078
Inventory 206,916
Total Current Assets  (as reported)529,583
Total Current Assets  (calculated)527,594
+/- 1,989
Long-term Assets
Property Plant Equipment 564,741
Long-term Assets Other 93,997
Long-term Assets  (as reported)674,794
Long-term Assets  (calculated)658,738
+/- 16,056

Liabilities & Shareholders' Equity

Total Current Liabilities240,187
Long-term Liabilities326,084
Total Stockholder Equity638,106
Total Current Liabilities
Short-term Debt 101,121
Short Long Term Debt 101,121
Accounts payable 126,156
Other Current Liabilities 12,910
Total Current Liabilities  (as reported)240,187
Total Current Liabilities  (calculated)341,308
+/- 101,121
Long-term Liabilities
Long term Debt 315,374
Long-term Liabilities  (as reported)326,084
Long-term Liabilities  (calculated)315,374
+/- 10,710
Total Stockholder Equity
Common Stock419,367
Retained Earnings 259,622
Other Stockholders Equity -40,883
Total Stockholder Equity (as reported)638,106
Total Stockholder Equity (calculated)638,106
+/-0
Other
Capital Stock419,367
Cash and Short Term Investments 143,600
Common Stock Shares Outstanding 946,829
Liabilities and Stockholders Equity 1,204,377
Net Debt 272,895
Net Invested Capital 1,054,601
Net Working Capital 289,396
Short Long Term Debt Total 416,495



Balance Sheet

Currency in MYR. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-31
> Total Assets 
201,782
197,931
195,539
198,030
203,809
213,667
217,013
205,652
225,811
218,296
227,022
222,477
239,183
541,930
660,529
633,446
642,424
632,404
639,069
661,463
694,557
689,041
711,265
705,240
745,045
802,944
835,128
836,378
875,922
910,726
907,542
919,801
959,496
1,007,333
997,257
1,058,432
1,105,955
1,096,800
1,179,185
1,164,131
1,203,979
1,204,377
1,204,3771,203,9791,164,1311,179,1851,096,8001,105,9551,058,432997,2571,007,333959,496919,801907,542910,726875,922836,378835,128802,944745,045705,240711,265689,041694,557661,463639,069632,404642,424633,446660,529541,930239,183222,477227,022218,296225,811205,652217,013213,667203,809198,030195,539197,931201,782
   > Total Current Assets 
100,895
94,283
93,140
92,620
100,271
104,410
105,821
94,188
112,077
104,145
113,226
106,854
119,497
268,193
383,497
354,346
362,345
351,875
358,035
365,182
386,552
377,126
378,229
356,619
385,017
391,482
395,610
367,330
396,476
431,540
429,803
417,205
452,220
486,727
444,683
459,693
510,357
458,509
536,337
494,796
526,260
529,583
529,583526,260494,796536,337458,509510,357459,693444,683486,727452,220417,205429,803431,540396,476367,330395,610391,482385,017356,619378,229377,126386,552365,182358,035351,875362,345354,346383,497268,193119,497106,854113,226104,145112,07794,188105,821104,410100,27192,62093,14094,283100,895
       Cash And Cash Equivalents 
11,024
1,846
4,777
14,139
18,443
20,311
19,580
18,879
18,028
6,805
15,859
18,303
30,485
31,320
142,797
143,510
146,900
122,574
132,326
114,814
111,651
82,917
86,800
96,021
76,749
77,211
94,073
98,254
73,967
96,170
92,123
120,669
126,726
163,674
129,965
158,029
149,270
109,073
109,696
137,980
152,548
143,600
143,600152,548137,980109,696109,073149,270158,029129,965163,674126,726120,66992,12396,17073,96798,25494,07377,21176,74996,02186,80082,917111,651114,814132,326122,574146,900143,510142,79731,32030,48518,30315,8596,80518,02818,87919,58020,31118,44314,1394,7771,84611,024
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
121,000
120,000
102,000
99,000
0
0
0
0
0
0
0
0
0
0
0
0
0
176,957
145,938
187,705
164,562
152,393
142,181
181,139
161,253
185,002
130,495
167,850
177,078
177,078167,850130,495185,002161,253181,139142,181152,393164,562187,705145,938176,957000000000000099,000102,000120,000121,0000000000000000
       Inventory 
43,500
46,797
47,558
41,383
39,614
39,783
36,758
36,331
52,961
55,682
52,077
44,644
45,736
116,145
121,055
103,467
116,429
121,427
122,717
139,101
143,068
146,761
152,718
136,303
131,394
137,595
139,498
139,607
144,444
152,261
158,656
144,003
130,302
148,792
152,870
151,266
175,925
184,903
238,931
222,192
203,153
206,916
206,916203,153222,192238,931184,903175,925151,266152,870148,792130,302144,003158,656152,261144,444139,607139,498137,595131,394136,303152,718146,761143,068139,101122,717121,427116,429103,467121,055116,14545,73644,64452,07755,68252,96136,33136,75839,78339,61441,38347,55846,79743,500
       Other Current Assets 
46,371
45,640
40,805
37,098
42,214
44,316
49,483
38,978
41,088
41,658
45,290
43,907
43,276
120,728
119,645
107,369
99,016
107,874
102,992
111,267
131,833
147,448
138,711
124,295
176,874
176,676
162,039
129,469
178,065
183,109
179,024
152,533
195,192
174,261
161,848
150,398
185,162
164,533
187,710
134,624
170,559
179,067
179,067170,559134,624187,710164,533185,162150,398161,848174,261195,192152,533179,024183,109178,065129,469162,039176,676176,874124,295138,711147,448131,833111,267102,992107,87499,016107,369119,645120,72843,27643,90745,29041,65841,08838,97849,48344,31642,21437,09840,80545,64046,371
   > Long-term Assets 
100,887
103,648
102,399
105,410
103,538
109,257
111,192
111,464
113,734
114,151
113,796
115,623
119,686
273,737
277,032
279,100
280,079
280,529
281,034
296,281
308,005
311,915
333,036
348,621
360,028
411,462
439,518
469,048
479,446
479,186
477,739
502,596
507,276
520,606
552,574
598,739
595,598
638,291
642,848
669,335
677,719
674,794
674,794677,719669,335642,848638,291595,598598,739552,574520,606507,276502,596477,739479,186479,446469,048439,518411,462360,028348,621333,036311,915308,005296,281281,034280,529280,079279,100277,032273,737119,686115,623113,796114,151113,734111,464111,192109,257103,538105,410102,399103,648100,887
       Property Plant Equipment 
95,167
97,928
96,679
98,940
97,068
98,102
99,692
98,902
101,096
100,859
100,106
101,060
104,600
248,585
250,413
269,290
267,604
269,401
269,231
276,241
286,952
289,205
306,688
321,335
335,231
338,175
360,453
386,182
394,041
401,928
404,264
412,248
416,060
424,708
432,013
441,789
460,174
501,672
521,520
542,525
559,559
564,741
564,741559,559542,525521,520501,672460,174441,789432,013424,708416,060412,248404,264401,928394,041386,182360,453338,175335,231321,335306,688289,205286,952276,241269,231269,401267,604269,290250,413248,585104,600101,060100,106100,859101,09698,90299,69298,10297,06898,94096,67997,92895,167
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,235
0
0
0
19,403
0
0
0
28,113
29,999
29,263
29,361
35,066
35,530
34,957
34,341
39,524
39,062
0
039,06239,52434,34134,95735,53035,06629,36129,26329,99928,11300019,40300016,23500000000000000000000000
       Long-term Assets Other 
5,720
5,720
5,720
6,470
6,470
11,155
11,500
11,500
11,500
11,500
11,500
11,500
11,500
13,300
13,300
1,000
1,000
1,000
1,000
1,000
1,000
1,000
0
1,200
1,200
45,513
50,913
53,263
55,646
47,759
42,432
53,039
51,590
56,271
80,812
113,347
91,070
93,179
113,102
74,586
104,629
93,997
93,997104,62974,586113,10293,17991,070113,34780,81256,27151,59053,03942,43247,75955,64653,26350,91345,5131,2001,20001,0001,0001,0001,0001,0001,0001,00013,30013,30011,50011,50011,50011,50011,50011,50011,50011,1556,4706,4705,7205,7205,720
> Total Liabilities 
30,629
35,008
26,174
27,527
26,606
25,775
36,910
23,003
34,797
38,496
38,539
28,847
34,420
351,687
212,347
183,728
184,863
185,683
186,007
206,947
230,175
226,466
237,285
225,375
254,398
316,669
335,052
355,337
377,828
406,994
399,126
390,051
418,454
423,391
402,836
414,611
467,172
482,957
566,849
540,127
568,508
566,271
566,271568,508540,127566,849482,957467,172414,611402,836423,391418,454390,051399,126406,994377,828355,337335,052316,669254,398225,375237,285226,466230,175206,947186,007185,683184,863183,728212,347351,68734,42028,84738,53938,49634,79723,00336,91025,77526,60627,52726,17435,00830,629
   > Total Current Liabilities 
25,477
29,856
21,022
21,868
21,198
20,558
31,742
18,554
31,201
34,970
33,901
23,347
28,921
230,029
90,638
74,712
75,820
77,117
87,067
103,156
128,266
134,644
140,244
121,659
149,834
188,149
186,213
222,445
244,949
265,496
248,158
239,442
263,741
266,381
182,965
150,321
198,873
196,426
253,798
230,309
240,686
240,187
240,187240,686230,309253,798196,426198,873150,321182,965266,381263,741239,442248,158265,496244,949222,445186,213188,149149,834121,659140,244134,644128,266103,15687,06777,11775,82074,71290,638230,02928,92123,34733,90134,97031,20118,55431,74220,55821,19821,86821,02229,85625,477
       Short-term Debt 
8,332
6,248
4,165
5,000
5,000
0
6,000
0
0
10,000
10,000
0
0
152,780
11,760
18,947
18,252
11,570
25,006
21,498
35,112
32,763
28,301
36,291
59,223
86,033
86,034
121,842
124,338
130,571
124,601
125,441
131,705
131,686
55,486
49,394
63,279
65,451
106,107
103,566
102,097
101,121
101,121102,097103,566106,10765,45163,27949,39455,486131,686131,705125,441124,601130,571124,338121,84286,03486,03359,22336,29128,30132,76335,11221,49825,00611,57018,25218,94711,760152,7800010,00010,000006,00005,0005,0004,1656,2488,332
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
265,000
124,000
123,000
122,000
0
0
0
0
0
0
0
0
0
0
0
0
0
124,601
124,663
131,705
131,686
55,486
48,793
63,279
65,451
106,107
102,925
102,097
101,121
101,121102,097102,925106,10765,45163,27948,79355,486131,686131,705124,663124,6010000000000000122,000123,000124,000265,0000000000000000
       Accounts payable 
15,714
22,536
15,045
16,822
14,454
14,222
16,266
17,159
27,491
18,155
18,855
21,624
21,215
64,473
64,382
55,765
53,032
46,295
42,665
0
71,262
77,450
87,807
19,055
66,003
75,846
85,306
31,202
119,979
134,560
123,141
34,670
131,223
132,346
125,854
22,933
134,745
127,207
141,291
31,323
129,192
126,156
126,156129,19231,323141,291127,207134,74522,933125,854132,346131,22334,670123,141134,560119,97931,20285,30675,84666,00319,05587,80777,45071,262042,66546,29553,03255,76564,38264,47321,21521,62418,85518,15527,49117,15916,26614,22214,45416,82215,04522,53615,714
       Other Current Liabilities 
1,431
1,072
1,812
46
1,744
6,336
9,476
1,395
3,710
6,815
5,046
1,723
7,706
12,776
14,496
35,000
4,536
19,252
19,396
81,658
21,892
24,431
24,136
66,313
24,608
26,270
14,873
69,401
632
365
416
79,331
813
2,349
1,625
77,994
849
3,768
6,400
95,420
9,397
12,910
12,9109,39795,4206,4003,76884977,9941,6252,34981379,33141636563269,40114,87326,27024,60866,31324,13624,43121,89281,65819,39619,2524,53635,00014,49612,7767,7061,7235,0466,8153,7101,3959,4766,3361,744461,8121,0721,431
   > Long-term Liabilities 
5,152
5,152
5,152
5,659
5,408
5,217
5,168
4,449
3,596
3,526
4,638
5,500
5,499
121,658
121,709
109,016
109,043
108,566
98,940
103,791
101,909
91,822
97,041
103,716
104,564
128,520
148,839
132,892
132,879
141,498
150,968
150,609
154,713
157,010
219,871
264,290
268,299
286,531
313,051
309,818
327,822
326,084
326,084327,822309,818313,051286,531268,299264,290219,871157,010154,713150,609150,968141,498132,879132,892148,839128,520104,564103,71697,04191,822101,909103,79198,940108,566109,043109,016121,709121,6585,4995,5004,6383,5263,5964,4495,1685,2175,4085,6595,1525,1525,152
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
208,410
253,281
257,254
275,643
299,797
297,797
316,703
0
0316,703297,797299,797275,643257,254253,281208,4100000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
8,000
9,000
7,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000007,0009,0008,0000000000000000
> Total Stockholder Equity
171,153
162,923
169,365
170,503
177,203
187,892
180,103
182,649
191,014
179,800
188,483
193,630
204,763
190,243
448,182
449,718
457,561
446,721
453,062
454,516
464,382
462,575
473,980
479,865
490,647
486,275
500,076
481,041
498,094
503,732
508,416
529,750
541,042
583,942
594,421
643,821
638,783
613,843
612,336
624,004
635,471
638,106
638,106635,471624,004612,336613,843638,783643,821594,421583,942541,042529,750508,416503,732498,094481,041500,076486,275490,647479,865473,980462,575464,382454,516453,062446,721457,561449,718448,182190,243204,763193,630188,483179,800191,014182,649180,103187,892177,203170,503169,365162,923171,153
   Common Stock
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
139,478
139,478
139,478
139,478
139,478
139,478
139,478
139,478
139,478
333,684
333,684
333,684
347,188
347,188
347,188
347,188
369,059
374,404
374,404
374,404
404,922
404,922
404,922
405,857
405,857
405,856
405,856
419,367
419,367405,856405,856405,857405,857404,922404,922404,922374,404374,404374,404369,059347,188347,188347,188347,188333,684333,684333,684139,478139,478139,478139,478139,478139,478139,478139,478139,47869,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,739
   Retained Earnings 
102,992
94,762
87,484
88,622
95,322
106,011
98,222
100,768
109,133
97,919
106,602
111,749
120,718
106,198
114,500
116,757
124,585
113,183
119,409
121,266
130,830
129,313
140,440
145,596
156,243
166,582
152,686
161,075
175,411
189,308
177,746
182,946
196,507
227,611
203,989
220,182
237,796
210,824
224,253
239,972
260,263
259,622
259,622260,263239,972224,253210,824237,796220,182203,989227,611196,507182,946177,746189,308175,411161,075152,686166,582156,243145,596140,440129,313130,830121,266119,409113,183124,585116,757114,500106,198120,718111,749106,60297,919109,133100,76898,222106,01195,32288,62287,48494,762102,992
   Capital Surplus 000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
-1,578
-1,578
12,142
12,142
12,142
12,142
12,142
12,142
12,142
12,142
12,142
12,142
14,306
14,306
194,204
193,483
193,498
194,060
194,175
193,772
194,074
193,784
194,062
585
720
-13,991
202
-27,222
-24,505
-32,764
-38,389
-27,600
-29,869
-18,073
-14,490
18,717
-3,935
-2,838
-17,774
-21,824
-30,648
-40,883
-40,883-30,648-21,824-17,774-2,838-3,93518,717-14,490-18,073-29,869-27,600-38,389-32,764-24,505-27,222202-13,991720585194,062193,784194,074193,772194,175194,060193,498193,483194,20414,30614,30612,14212,14212,14212,14212,14212,14212,14212,14212,14212,142-1,578-1,578



Balance Sheet

Currency in MYR. All numbers in thousands.




Cash Flow

Currency in MYR. All numbers in thousands.




Income Statement

Currency in MYR. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue639,175
Cost of Revenue-385,191
Gross Profit253,984253,984
 
Operating Income (+$)
Gross Profit253,984
Operating Expense-165,123
Operating Income88,75988,861
 
Operating Expense (+$)
Research Development-
Selling General Administrative71,134
Selling And Marketing Expenses94,650
Operating Expense165,123165,784
 
Net Interest Income (+$)
Interest Income-5,774
Interest Expense-6,439
Net Interest Income-5,776-12,213
 
Pretax Income (+$)
Operating Income88,759
Net Interest Income-5,776
Other Non-Operating Income Expenses-
Income Before Tax (EBT)82,98394,535
EBIT - interestExpense = 82,983
82,983
72,122
Interest Expense6,439
Earnings Before Interest and Taxes (ebit)89,42289,422
Earnings Before Interest and Taxes (ebitda)121,377
 
After tax Income (+$)
Income Before Tax82,983
Tax Provision-17,300
Net Income From Continuing Ops65,68365,683
Net Income65,683
Net Income Applicable To Common Shares65,683
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses550,314
Total Other Income/Expenses Net-5,7765,776
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
CLA.MI
now

I found you a Oversold RSI (Relative Strength Index) on the daily chart of CLA.MI.

CLA.MI Daily Candlestick Chart
DKIFJIX.CO
now

I found you a Oversold RSI (Relative Strength Index) on the daily chart of DKIFJIX.CO.

DKIFJIX.CO Daily Candlestick Chart
PARKEN.CO
now

I found you a Oversold RSI (Relative Strength Index) on the daily chart of PARKEN.CO.

PARKEN.CO Daily Candlestick Chart
HWKZ.NYSE
now

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HWKZ.NYSE.

HWKZ.NYSE Daily Candlestick Chart
STXIND.JSE
now

I found you a Death Cross on the daily chart of STXIND.JSE.

STXIND.JSE Daily Candlestick Chart
STXEMG.JSE
now

I found you a Oversold RSI (Relative Strength Index) on the daily chart of STXEMG.JSE.

STXEMG.JSE Daily Candlestick Chart
01003T.TW
2 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 01003T.TW.

01003T.TW Daily Candlestick Chart
BTI.JSE
2 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of BTI.JSE.

BTI.JSE Daily Candlestick Chart
VALUEGFO.MX
3 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VALUEGFO.MX.

VALUEGFO.MX Daily Candlestick Chart
BERI.LSE
3 minutes ago

I found you a Golden Cross on the daily chart of BERI.LSE.

BERI.LSE Daily Candlestick Chart
XLDX.SW
3 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of XLDX.SW.

XLDX.SW Daily Candlestick Chart
KING.OL
3 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of KING.OL.

KING.OL Daily Candlestick Chart
EMYB.OTCQX
5 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of EMYB.OTCQX.

EMYB.OTCQX Daily Candlestick Chart
NGK24-NYM.COMM
6 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGK24-NYM.COMM.

NGK24-NYM.COMM Daily Candlestick Chart
LBC.V
6 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of LBC.V.

LBC.V Daily Candlestick Chart
SVB.TO
6 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SVB.TO.

SVB.TO Daily Candlestick Chart
CPG.TO
7 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of CPG.TO.

CPG.TO Daily Candlestick Chart
CHR.TO
7 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of CHR.TO.

CHR.TO Daily Candlestick Chart
HLS.TO
7 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of HLS.TO.

HLS.TO Daily Candlestick Chart
MRT-UN.TO
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MRT-UN.TO.

MRT-UN.TO Daily Candlestick Chart
TCLV.TO
7 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of TCLV.TO.

TCLV.TO Daily Candlestick Chart
SPTSX60.INDX
7 minutes ago

I found you a Bearish Three Line Strike Candle Pattern on the daily chart of SPTSX60.INDX.

SPTSX60.INDX Daily Candlestick Chart
ADVA.INDX
10 minutes ago

I found you a Golden Cross on the daily chart of ADVA.INDX.

ADVA.INDX Daily Candlestick Chart
GEM.OL
10 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GEM.OL.

GEM.OL Daily Candlestick Chart